Speaker Bios for Spring 2010

© 2017

Albert S. Chan, MD, MS, FAAFP
Electronic Health Record Physician Champion, Palo Alto Medical Foundation
Albert S. Chan, M.D., M.S. (Biomedical Informatics), FAAFP is the Electronic Health Record Physician Champion of the Palo Alto Medical Foundation (PAMF) and Medical Director of PAMFOnline. Albert works with his fellow physicians and colleagues in clinical operations to design and optimize the use of the electronic health record at PAMF and provider/patient use of PAMFOnline, a linked personal health record for PAMF patients. He is co-chair of the Sutter Health Ambulatory Decision Support Working Group, which develops clinical decision support shared both by clinicians in the EHR and patients in the PHR. Albert has \ a special interest in leveraging personal health records to promote patient-centric care and shared decision making in chronic disease management. He is the study physician of EMPOWER-D (Engaging and Motivating Patients Online With Enhanced Resources?for Diabetes), an AHRQ-funded randomized clinical trial on the use of personal health records and remote patient monitoring in the management of diabetes. Albert also serves as Co-Chair of California Health and Human Services Agency's Patient Engagement Work Group, identifying innovative approaches to engaging and empowering patients and their families through the use of techn\ ology that harnesses the HIE infrastructure, and recommend how to incorporate these approaches into the State?s HIE services. He previously served as Co-Chair of the Certification Commission for Health Information Technology (CCHIT) Personal Health Records Work Group.

Prior to joining PAMF, Albert concurrently completed a post-doctoral fellowship in Biomedical Informatics at Stanford University and a research fellowship at the University of California, San Francisco. His post-doctoral work in the lab of Mary Goldstein, MD, MS centered on the evaluation of physician behavior with ATHENA DSS, a guideline-based decision support system with point-of-care recommendations to physicians for the treatment of hypertension. He obtained a BS in Biological Sciences from Stanford University and Medical Doctorate from the University of California, San Diego. He completed his residency and year as\ chief resident in family medicine at the San Jose Medical Center Family Practice Residency, a residency program affiliated with Stanford University of School of Medicine.


Geoffrey Rutledge, MD, PhD
Chief Medical Officer and EVP of Product Development, Epocrates
Prior to joining Epocrates, Dr. Rutledge served as chief information officer at Wellsphere, a top online health site with more than seven million monthly visits. During his tenure at San Mateo Medical Center, Dr. Rutledge was responsible for the strategy and implementation of highly successful outpatient and emergency department clinical information system services. In senior management positions at First Consulting Group and WebMD, he helped direct the companies' visions and develop key initiatives. Dr. Rutledge has practiced clinical medicine for more than 25 years, is board certified in internal and emergency medicine and\ is a former faculty member of Harvard Medical School and Stanford University School of Medicine.

Dr. Rutledge received a Bachelor of Science in Cell and Molecular Biology and his medical degree from McGill University in Montreal, Canada. He completed his internship and residency in Internal Medicine at UCSD Medical Center and earned a Ph.D. in Medical Information Sciences from Stanford University. Dr. Rutledge is board certified in Internal Medicine, Emergency Medicine, Advanced Cardiac Life Support (ACLS), Advanced Trauma Life Support (ATLS), and is a former ATLS instructor. He has received a number of scholarships and achievement awards, including the Outstanding Consultant Award from the Annals of Emergency Medicine\ / American College of Emergency Physicians and recognition in the current edition of ?Guide to America?s Top Physicians.?

Dr. Rutledge was also a founder and Vice President of Clinical Transformation for First Consulting Group, Inc, as well as founder and Vice President of Business Development/Executive Director of WebMD Canada. Additionally, he co-founded the academic division of Emergency Medicine at Boston Beth Israel Hospital at Harvard Medical School. He has also delved into research and technology, developing advanced devices to monitor the treatment of critical patients in the ICU.

Dr. Rutledge is an expert-rated hang-glider pilot, an active private airplane pilot, a scuba diver, and proud owner of a beautiful Belgian Malinois.


Alan H. Roter, PhD
VP Informatics, Entelos
Dr. Roter joined Entelos in 2007 with the acquisition of Iconix Biosciences. He was the Vice President of Informatics at Iconix since its founding in January 1998, and led the software and informatics development of DrugMatrix? and ToxFX?. Previous to that he was Director of Computational Biology for Sequana Therapeutics. Dr. Roter joined Sequana as a founding employee in 1993. At Sequana, Dr. Roter led a bioinformatics team of 13 scientists to develop systems for high throughput sequencing, physical mapping, automated sequence annotation and candidate gene analysis. Dr. Roter was also responsible for establishing Sequana's \ bioinformatics systems for high-throughput genotyping. From 1988 to 1993, Dr. Roter worked at Applied Biosystems where he authored software for the 373B Automated DNA Sequencer, the established standard in the genomics research community. His academic training includes a Ph.D. in Developmental Biology from the University of Chicago, and a BS in Biology from the University of Illinois at Urbana-Champaign.

David Johnson, PhD
Chief Operating Officer, Gene Security Network
Dr. David S. Johnson is a highly regarded expert in genomics and has commercialized multiple industry-leading diagnostic technologies. Prior to working in the private sector, Dr. Johnson obtained a Ph.D. in Genetics from Stanford University, and was ENCODE Project Director at the Stanford Human Genome Center. At the Genome Center, Dr. Johnson invented several innovative approaches for genome-wide molecular analysis using next-generation sequencing technologies. His work culminated with a frequently cited article in Science magazine and a successful $14.6 million grant from the National Human Genome Research Institute (NHGRI). After Stanford, Dr. Johnson was among the founding members of Gene Security Network (GSN), a Silicon Valley genetics startup funded by Sequoia Capital, Alafi Capital, and Claremont Creek Ventures. At GSN, Dr. Johnson was ultimately promoted to Chief Operating Officer, responsible for all clinical laboratory operations, laboratory research, clinical studies, and clinical product development. As COO, Dr. Johnson led invention and commercialization of two clinical products for preimplantation genetic diagnosis (PGD), which have reached monthly sales of approximately $250k less than a year after commercial launch. These PGD products are among the first widely adopted clinical applications of DNA microarrays. Additionally, he authored two successful SBIR grants from the National Institute of Child Health and Human Development (NICHD), for a total of approximately $3.6 million in research funding. Recently, he has published his work at GSN in the journal Human Reproduction. Most recently Dr. Johnson is founder and CEO of a new genetics venture, GigaGen, Inc., whose primary mission is to bring next-generation sequencing into clinical practice. Dr. Johnson has lectured internationally and has been an instructor at Stanford University.

John Sninsky, Ph.D is the Vice President of Discovery Research at Celera. The Discovery Research group encompasses teams of scientists who work in: specific disease areas, a high-throughput genotyping and expression facility, statistical genetics, biomarker development, computational biology and future diagnostic technologies. His primary focus is the application of genetic and genomic tools to identify and develop diagnostic and pharmacogenomic assays for common complex disease and cancer. He is the author of numerous scientific papers including methods in molecular biology, application of the polymerase chain reacti\ on (PCR) to virology and cancer, and more recently genome-wide genetic association studies for multiple common, complex diseases.

Among Dr. Sninsky?s past awards are the Centers for Disease Control Charles C. Shepherd Science Award (1988), the Pan American Society for Clinical Virology Award (1992) and the Hoffmann-La Roche R & D Prize in 1997 for his efforts in applying PCR to virology and developing assays for measuring viral load in individuals with (HIV) AIDS.

Dr. Sninsky was a recipient of the Purdue University Distinguished Alumni Award in 2001, and served on the Department of Biological Sciences Alumni Advisory Committee (2005-2007) before joining the Dean of College of Science Leadership Council in 2007. In addition, Dr. Sninsky is a member of the scientific advisory committee for the Charles R. Bronfman Institute for Personalized Medicine at Mount Sinai School of Medicine and chairs the scientific advisory panel for the Professional Science Masters (PSM) Program with an emphasis on Biotechnology and Stem Cell Science at San Francisco State University (SFSU).

Among Dr. Sninsky?s professional society memberships are American Association for the Advancement of Science, Association of Molecular Pathologists, American Society Human Genetics, American College Medical Genetics, American Association Cancer Research and American Association for the Study of Liver Disease.

Dr. Sninsky received a bachelor?s degree in biology from Bates College (1972) and a Ph.D. in biology from Purdue University (1976). He was a postdoctoral fellow in Genetics and Medicine at Stanford University School of Medicine with Stanley N. Cohen. From 1981 to 1984, Dr. Sninsky was on the faculty at Albert Einstein College of Medicine (AECOM) in the Department of Microbiology and Immunology with a joint appointment in the Department of Molecular Biology. He was a member of the AECOM Liver and Cancer Centers. From 1984 to 1991, he worked at Cetus Corporation where he was responsible for the immunoassay and molecular diagn\ ostics programs.

From 1991 to 1998, John was the Senior Director of Research at Roche Molecular Systems. His team of scientists devised PCR diagnostic assays for many infectious pathogens as well as for genetic diseases and cancer. In 1998, he was promoted to Vice President, Discovery Research as well as Vice President, Roche Genetics, an initiative that coordinated the genetic and genomic efforts between the pharmaceutical and diagnostics divisions. Dr. Sninsky joined Celera in 2000.


West Shell III
Chairman and CEO, Healthline Netowrks
In April 2005, West joined the Board of Directors and assumed the role of chairman and CEO of Healthline. Prior to joining Healthline, West served as CEO and president of Sapias, a leading provider of mobile workforce management solutions for large enterprise customers such as Time Warner, ServiceMaster, and Hudson News. From 1997 to 2001, as chairman and CEO of Netcentives, West created one of the most powerful e-marketing companies, managing over 50 million consumer relationships on behalf of more than 200 blue chip customers in 10 countries. Within three years the company was generating over $70 million in revenues. West \ successfully led an IPO and, during his tenure, raised more than $150 million in private and public funds from leading investors to a $3 billion market capitalization. West earlier co-founded and served as managing partner of Pacific Marketing Group, one of the largest independent marketing agencies on the West coast, which he sold to D'arcy, Masius, Benton and Bowles. West has also held various product management and marketing positions at Atari, Coopervision, Grey Advertising (P&G) and Johnson & Johnson. He currently also serves on the boards of California Trout and the Golden Gate National Parks Conservancy. He is happily\ married with four children and is an avid kayaker, skier and fly fisherman.

Healthline Networks is a leading provider of intelligent health information services, enabling over 90 million consumers a month to make more confident, informed healthcare decisions. The company's proprietary consumer healthcare taxonomy, the largest of its kind, powers a suite of intelligent health search, content and advertising services. Combining advanced search technology with deep medical expertise, Healthline partners with a network of over 40 trusted destination sites that include publishers, portals, search engines, employers and health plans. Headquartered in San Francisco, Healthline is backed by Aetna, GE/NBC Pe\ acock Fund, Investor Growth Capital, Kaiser Permanente, Reed Elsevier, U.S. News & World Report, and VantagePoint Venture Partners. For more information visit http://www.healthline.com.


Andrew Kasarkis
Senior Director, Pacific Biosciences
Andrew Kasarskis is currently Senior Director at Pacific Biosciences, where he is focused on identifying and developing the best applications for single molecule real time technologies. Prior to that, he helping to launch Sage Bionetworks, a nonprofit medical research organization dedicated to advancing human health by open application of systems biology to biomedical as Head of Strategic Initiatives and was an Affiliate Investigator of the Fred Hutchison Cancer Research Center. Sage built on work done by the Genetics Department at Merck Research Laboratories, where Andrew served as Scientific Director and built the depart\ ment from 2004-2009. The Merck Genetics Department worked across clinical, preclinical, and basic research to deliver novel drug targets and biomarkers and was grounded in the same systems approach to reconstructing the gene networks underpinning human biology and disease that is carried forward at Sage.

Andrew has focused his career on addressing urgent biological problems by developing and applying cutting-edge technology. From 1998-2000 he contributed to the development of the Gene Ontology, Stanford Microarray Database, and Saccharomyces Genome Database while a member of the Genome Databases Group at Stanford University. In 2000, he moved to DoubleTwist, Inc., where he served as Senior Product Manager and was responsible for the commercial success and scientific validity of the Prophecy Genome Database and software suite. In 2002, he joined Merck Research Laboratories at the Rosetta site in Seattle, WA as a Senior Sci\ entist in Informatics. During his seven-year tenure at Merck he had responsibility for a variety of laboratory research and software initiatives, all focused on the generation, integration, and effective use of complex orthogonal data sets to create increasingly predictive models of human disease.

Andrew holds a Ph.D. in Molecular and Cellular Biology from UC Berkeley as well as a B.S. in Biology and a B.A. in Chemistry from the University of Kentucky.


Ilya Kupershmidt
Co-founder & VP Products, NextBio
Ilya leads NextBio's product and scientific computing teams. Prior to NextBio, he was the head of bioinformatics group at Silicon Genetics where he developed solutions for the analysis and management of high throughput data from genomic and proteomic technologies. He joined Silicon Genetics as an early stage startup and worked until its acquisition by Agilent technologies in 2004. In parallel to NextBio Ilya is working on finishing his PhD thesis work at the KTH Institute in Stockholm. Ilya holds B.S. from University of California San Diego in Molecular Biology and Genetics. While at UCSD, he also carried out research at the Howard Hughes Medical Institute for several years before going into industry.